Mefloquine

• UNSPSC Description:

  Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research[1][2][3].

• Target Antigen:

  Autophagy; Parasite; Potassium Channel; ROS Kinase; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Autophagy;Membrane Transporter/Ion Channel;Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mefloquine.html

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  O[C@H]([C@]1([H])NCCCC1)C2=CC(C(F)(F)F)=NC3=C(C(F)(F)F)C=CC=C32

• Molecular Weight:

  378.31

• References & Citations:

  [1]Kang J, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK andHERG. J Pharmacol Exp Ther. 2001 Oct;299(1):290-6.|[2]Yan KH, et al. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncol Lett. 2013 May;5(5):1541-1545.|[3]Kaho Shionoya, et al. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021 Apr 30;12:651403.|[4]Rafael Pacheco-Costa, et al. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 Sep;114:22-31.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  53230-10-7